Modulations of human resting brain connectivity by kisspeptin enhance sexual and emotional functions

Kingsberg S.A. et al.

The pivotal RECONNECT trials (Studies 301 and 302) that got bremelanotide FDA-approved for HSDD in premenopausal women. Statistically significant improvements in desire and distress on validated scales; effect sizes are real but modest, and discontinuation for nausea is the practical limiter.

Simon J.A. et al.

The 52-week open-label extension to RECONNECT. Tolerability stays bumpy — nausea, flushing, transient blood-pressure rises — but the women who continued kept the desire and distress gains. The longest-duration PT-141 dataset that exists in humans.

Comninos A.N. et al.

The Dhillo group's fMRI work showing IV kisspeptin shifts limbic activity in heterosexual men during sexual and emotional image processing. Mechanism, not therapy — but the cleanest human evidence that kisspeptin acts above the hypothalamus, not just within it.

Dhillo W.S. et al.

The first-in-human kisspeptin paper. IV kisspeptin-54 raised LH, FSH, and testosterone in healthy men — proving the rodent biology translates. Everything written since about kisspeptin as a fertility and reproductive-endocrinology tool starts here.